These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 28618904)

  • 1. Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.
    Lettino M; Leonardi S; De Maria E; Halvorsen S
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):61-70. PubMed ID: 28618904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Vandvik PO; Lincoff AM; Gore JM; Gutterman DD; Sonnenberg FA; Alonso-Coello P; Akl EA; Lansberg MG; Guyatt GH; Spencer FA
    Chest; 2012 Feb; 141(2 Suppl):e637S-e668S. PubMed ID: 22315274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
    Spinthakis N; Farag M; Akhtar Z; Gorog DA
    Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic treatment in peripheral artery disease.
    Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
    Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Prog Cardiovasc Dis; 2015; 58(3):267-77. PubMed ID: 26277706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
    Sumaya W; Geisler T; Kristensen SD; Storey RF
    Thromb Haemost; 2019 Oct; 119(10):1583-1589. PubMed ID: 30836389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction.
    Park Y; Franchi F; Rollini F; Angiolillo DJ
    Trends Cardiovasc Med; 2016 May; 26(4):321-34. PubMed ID: 26391344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
    Poredos P; Jezovnik MK
    Vasa; 2013 Mar; 42(2):88-95. PubMed ID: 23485835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
    Huber K; Bates ER; Valgimigli M; Wallentin L; Kristensen SD; Anderson JL; Lopez Sendon JL; Tubaro M; Granger CB; Bode C; Ohman EM; Steg PG
    Am Heart J; 2014 Nov; 168(5):611-21. PubMed ID: 25440788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized antithrombotic therapy.
    Lüscher TF; Steffel J
    Hamostaseologie; 2016; 36(1):26-32. PubMed ID: 25597592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on-treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)-2 Trial.
    Ying L; Wang J; Li J; Teng J; Zhang X; Ullah I; Samee A; Xu K; Chen J; Xu L; Zhu H; Li J; Yang L; Wang F; Fan Y; Zhang J; Lu Y; Gong X; Shi L; Eikelboom JW; Li C
    Br J Haematol; 2022 Jan; 196(2):424-432. PubMed ID: 34611892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined antiplatelet therapy: still a sweeping combination in cardiology.
    Manolis AS; Manolis TA; Papadimitriou P; Koulouris S; Melita H
    Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):136-67. PubMed ID: 23597106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Clopidogrel in 2020: A Reappraisal.
    Patti G; Micieli G; Cimminiello C; Bolognese L
    Cardiovasc Ther; 2020; 2020():8703627. PubMed ID: 32284734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.